HC Wainwright Issues Negative Outlook for CTMX Earnings

Key Points

• HC Wainwright has downgraded its Q3 2025 EPS estimate for CytomX Therapeutics from $0.02 to $0.00, while maintaining a "Buy" rating with a $5.00 price target.
• Other analysts have varied ratings on the stock, with Wedbush setting a price target of $6.00 and Piper Sandler increasing their target to $5.00, contributing to an average price target of $5.75.
• The stock opened at $2.31 with a market cap of $186.23 million, and has had significant hedge fund interest, with institutional investors owning approximately 67.77% of the company's stock.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - HC Wainwright cut their Q3 2025 EPS estimates for CytomX Therapeutics in a research report issued on Monday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.02. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q4 2025 earnings at $0.00 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.00 EPS and Q3 2026 earnings at ($0.01) EPS.

A number of other research analysts have also recently issued reports on the stock. Wedbush restated an "outperform" rating and set a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a report on Monday, May 12th. Piper Sandler boosted their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. Wall Street Zen upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. Finally, Oppenheimer initiated coverage on shares of CytomX Therapeutics in a report on Thursday, July 31st. They issued an "outperform" rating and a $7.00 price target for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $5.75.

CytomX Therapeutics Stock Performance

Shares of NASDAQ CTMX opened at $2.31 on Tuesday. The stock has a market cap of $186.23 million, a P/E ratio of 4.13 and a beta of 2.13. The firm has a 50 day moving average price of $2.40 and a 200 day moving average price of $1.47. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $3.10.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The firm had revenue of $50.92 million during the quarter, compared to analysts' expectations of $35.42 million. CytomX Therapeutics had a net margin of 34.04% and a return on equity of 158.70%. During the same quarter in the previous year, the company earned $0.17 earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CTMX. Point72 Asset Management L.P. acquired a new position in shares of CytomX Therapeutics in the fourth quarter valued at approximately $2,730,000. Woodline Partners LP acquired a new position in CytomX Therapeutics during the first quarter worth $1,054,000. RA Capital Management L.P. acquired a new position in CytomX Therapeutics during the first quarter worth $636,000. Geode Capital Management LLC boosted its holdings in CytomX Therapeutics by 103.4% during the second quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company's stock worth $3,963,000 after purchasing an additional 887,218 shares during the last quarter. Finally, Prosight Management LP boosted its holdings in CytomX Therapeutics by 29.2% during the fourth quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company's stock worth $4,022,000 after purchasing an additional 882,891 shares during the last quarter. Institutional investors and hedge funds own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.